Evolent Health (NYSE:EVH) Raised to “Hold” at Wall Street Zen

Evolent Health (NYSE:EVH) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other research analysts have also issued research reports about the stock. Piper Sandler set a $6.00 price target on shares of Evolent Health in a report on Tuesday, December 2nd. Royal Bank Of Canada dropped their target price on shares of Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Oppenheimer cut their price target on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 12th. Stephens raised Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price objective for the company in a research report on Thursday, November 13th. Finally, BTIG Research dropped their price objective on Evolent Health from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.50.

Evolent Health Stock Down 2.0%

Shares of NYSE:EVH opened at $3.26 on Friday. The firm has a market cap of $363.26 million, a P/E ratio of -0.63 and a beta of 0.24. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 2.34. Evolent Health has a 12-month low of $2.50 and a 12-month high of $12.06. The business has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $5.75.

Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $468.72 million for the quarter, compared to the consensus estimate of $468.48 million. Evolent Health had a positive return on equity of 1.49% and a negative net margin of 28.49%.The business’s quarterly revenue was down 27.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.02) EPS. Analysts predict that Evolent Health will post 0.08 earnings per share for the current year.

Institutional Trading of Evolent Health

Large investors have recently modified their holdings of the business. Alpine Global Management LLC bought a new stake in shares of Evolent Health during the 4th quarter valued at about $175,000. Aristides Capital LLC purchased a new stake in Evolent Health in the fourth quarter worth about $195,000. Virtu Financial LLC purchased a new stake in Evolent Health in the fourth quarter worth about $106,000. Invesco Ltd. boosted its position in Evolent Health by 30.4% during the 4th quarter. Invesco Ltd. now owns 392,282 shares of the technology company’s stock valued at $1,569,000 after acquiring an additional 91,370 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Evolent Health during the 4th quarter worth approximately $109,000.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: BTIG set a new $8.00 price target for EVH, signaling confidence that the stock has upside from current levels. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Positive Sentiment: UBS lowered its target to $5.00 but kept a “buy” rating, implying upside (reported as ~54% above the then-current price). UBS lowers price target to $5.00
• Positive Sentiment: Citigroup cut its target to $4.00 but maintained a “buy” rating, which suggests analysts still see recovery potential despite near-term weakness. Citigroup lowers price target to $4.00
• Positive Sentiment: Seeking Alpha published a bullish-themed piece arguing EVH is “cheap, levered, but ready to rebound,” which can attract value-oriented buyers. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Evolent announced executive participation in upcoming investor conferences with live webcasts — useful for transparency but unlikely to move the stock materially on its own. Evolent to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Yahoo Finance ran a roundup noting a sharp intraday move earlier; such coverage increases attention/volatility but doesn’t change fundamentals. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Neutral Sentiment: Royal Bank of Canada set a $3.00 target — a lower valuation point that may anchor some expectations but was published alongside other divergent targets. Evolent Health (NYSE:EVH) Given New $3.00 Price Target at Royal Bank Of Canada
• Neutral Sentiment: Needham published a $4.00 price target; another mid-range projection adding to the wide spread of analyst views. Evolent Health (NYSE:EVH) Given New $4.00 Price Target at Needham & Company LLC
• Negative Sentiment: KeyCorp lowered EVH to “Sector Weight” (a downgrade), which is a clear negative signal and likely contributed to selling pressure. Evolent Health (NYSE:EVH) Rating Lowered to “Sector Weight” at KeyCorp

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.